Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025

NCT03907540 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Autoimmune Diseases
Fibrosis

Interventions

DRUG: Belumosudil 200 mg tablet
DRUG: [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose
DRUG: [14C]-KD025 200 mg capsule

Sponsor

Kadmon Corporation, LLC

Collaborators

[object Object]